一品紅(300723.SZ):子公司鹽酸氨溴索滴劑獲藥品註冊證書
格隆匯3月15日丨一品紅(300723.SZ)宣佈,公司全資子公司廣州一品紅製藥有限公司於近日收到國家藥品監督管理局核准簽發關於鹽酸氨溴索滴劑的《藥品註冊證書》。
公司研發的鹽酸氨溴索滴劑適用於痰液粘稠而不易咳出者,包括低齡幼兒,説明書中註明明確的兒童用法用量。根據IMS數據統計,氨溴索2019年市場銷售額為30.56億元。該品為國內首家按照一致性評價通過的鹽酸氨溴索口服液體制劑,且滴劑劑型目前為國內獨家所有。
此次獲得鹽酸氨溴索滴劑註冊證書,標誌着公司具備了在國內市場銷售該藥品的資格,將進一步豐富公司兒童藥產品的管線和品類,增強公司在兒童藥領域的競爭力,對公司業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.